Drug discovery

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy

Retrieved on: 
Tuesday, April 2, 2024
Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Machine learning, Informatics, Computational chemistry, Chem, Creativity, Drug discovery

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.

Key Points: 
  • X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.
  • Dr. Davis brings extensive experience in the areas of data strategy, informatics, computational chemistry and software solutions in drug discovery.
  • The addition of Dr. Davis to X-Chem’s executive team bolsters X-Chem’s strategy of leveraging its data generation platforms and deploying digitized drug discovery solutions to its clients.
  • “I am so excited to see Erin join the amazing team we have here at X-Chem,” said Karen Lackey, chief executive officer.

Phenovista Appoints Ellen Berg, PhD, an Expert in the Mechanisms of Drug and Disease Biology and Cell-Based Assays, to its Scientific Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Health, Research, Radiology, Pharmaceutical, Science, Biotechnology, Findability, Reusability, Drug discovery, Chemical safety, Biomedical Research, Doctor of Philosophy, Biology, Accessibility, Chemistry, Data, FAIR, Data management, North American Menopause Society, Animal, Interoperability

Dr. Berg is the Founder of Alto Predict and is an expert in human cell-based in vitro assays and platforms for drug discovery and chemical safety applications.

Key Points: 
  • Dr. Berg is the Founder of Alto Predict and is an expert in human cell-based in vitro assays and platforms for drug discovery and chemical safety applications.
  • “We are thrilled to announce that Ellen is joining our Scientific Advisory Board,” said James Evans, PhD, Chief Executive Officer of Phenovista.
  • She has a background in biopharmaceutical research and drug discovery contract research services with startup, operations, and commercialization experience.
  • Her research interests include mechanisms of human disease biology and drug action, predictive toxicology, and research information science, including AI/ML approaches and data visualization.

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Schizophrenia, Drug discovery, Patient, DSM-IV codes, Safety, Therapy, Allosteric regulation, Pharmaceutical industry

Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.

Key Points: 
  • Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.
  • The platform has a track record of identifying highly selective, brain penetrant small molecule drugs, a class that has the potential to revolutionize the treatment of neurological disorders.
  • Neurosterix’s lead program is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (“M4 PAM”) for the treatment of patients suffering from schizophrenia.
  • However, Neurosterix will accelerate its pursuit of these exciting medicines through acquiring Addex’s industry-leading proprietary high-throughput allosteric modulator drug discovery platform and a portfolio of preclinical neuroscience assets.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Genetics, Health, Diagnosis, PCR, Growth, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Entrepreneurship, Drug discovery, Patient, NEK1, Biology, Computational chemistry, Harmonic, Therapy, Multimedia, Polypharmacology

Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Key Points: 
  • Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240401176466/en/
    “We believe that the dark kinase NEK1 holds great potential as a drug target for developing cancer therapies addressing important resistance challenges in the clinic,” said Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine.
  • Harmonic will assume responsibilities for computational chemistry and medicinal chemistry activities, while Turbine will be responsible for in silico simulations and wet-lab validation of target biology, including the identification of both synergistic kinase co-targets to NEK1 and patient populations most likely to benefit from therapies.

Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases

Retrieved on: 
Thursday, March 28, 2024
Technology, Research, Other Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, GPCR, Obesity, Drug discovery, G protein-coupled receptor, Therapy, CSO, VHH, DSM-IV codes, Pharmaceutical industry

Confo Therapeutics , a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

Key Points: 
  • Confo Therapeutics , a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
  • The 2-year grant will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.
  • Class B GPCRs are recognized as important targets for new medicines, particularly in chronic endocrine and metabolic diseases.
  • Cedric Ververken, CEO of Confo Therapeutics, commented: “Receiving this additional VLAIO grant will strengthen our existing small molecule and antibody discovery efforts on high-value Class B GPCRs, which further paves the way to unlock new treatments for a range of endocrine and metabolic indications including obesity.

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

Retrieved on: 
Thursday, March 28, 2024
Research, Technology, Infectious Diseases, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Innovation, Entrepreneurship, Data analysis, Drug discovery, AI, IRIS, Doctor of Philosophy, InterSystems, Pharmaceutical industry

This collaboration integrates the new vector search capability of the InterSystems IRIS® data platform with IPA’s subsidiary BioStrand's LENSai platform, setting a new standard for AI-driven applications in healthcare and life sciences.

Key Points: 
  • This collaboration integrates the new vector search capability of the InterSystems IRIS® data platform with IPA’s subsidiary BioStrand's LENSai platform, setting a new standard for AI-driven applications in healthcare and life sciences.
  • This collaboration signifies a leap in technological advancement for addressing challenges with increasing volumes of data that the healthcare and life sciences industries are contending with today.
  • This innovative integration marries the precision of Vector Search, which enables efficient and accurate retrieval of relevant information from massive datasets using vector embeddings, with the depth of analysis provided by LENSai Universal Foundation AI Model and BioStrand's patented HYFT Technology.
  • Enhanced Integration and Scalability: By providing LENSai capabilities within the InterSystems IRIS data platform, companies in healthcare and life sciences gain a tool that seamlessly integrates with their existing infrastructure, offering scalability and enhanced performance without compromising security.

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

Noetik Appoints Dr. Shafique Virani as Chief Business Officer

Retrieved on: 
Wednesday, March 27, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Recursion, Neuromyelitis optica spectrum disorder, University, Drug discovery, Patient, Cancer, Medicine, Doctor of Philosophy, Bayer, Therapy, COA, Machine learning, CSO, Multimedia, Pharmaceutical industry

Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.

Key Points: 
  • Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240327236059/en/
    "We are thrilled to welcome Shaf to our team as Chief Business Officer.
  • Prior to joining Noetik, Dr. Virani served as Recursion’s Chief Corporate Development Officer, as well as the interim Chief Medical Officer as part of his tenure.
  • As Chief Business Officer, Dr. Virani will accelerate Noetik’s mission through both business development and portfolio strategy by identifying and facilitating strategically impactful transactions.